Karyopharm announced an investor conference call following the June 2, 2026 ASCO oral presentation of full Phase 3 SENTRY trial results evaluating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.
YolTech Therapeutics raised $70M in a Series C financing to expand what is currently one of China’s most advanced in vivo CRISPR and base-editing platforms, with programs spanning sickle cell disease, beta-thalassemia, ATTR, familial…
Blood Cancer United announced more than 50 ASCO and EHA 2026 abstracts, highlighted by an oral EHA presentation from the randomized Phase 2 OPTI-AML substudy evaluating reduced-duration venetoclax dosing with azacitidine in newly diagnosed…
Waypoint Bio emerged from stealth with a $20M Series A financing to advance multiple CAR-T investigator-initiated trials in China while developing an AI-enabled spatial pooled screening platform for next-generation target discovery.
Bristol Myers Squibb announced a strategic enterprise partnership with Anthropic to deploy Claude Enterprise across research, clinical development, manufacturing, regulatory, and commercial operations.
Wave Life Sciences reported positive updated data from the RestorAATion-2 study of WVE-006, demonstrating substantial restoration of functional alpha-1 antitrypsin protein and significant reduction of toxic mutant protein in Alpha-1 Antitrypsin Deficiency (AATD).
Beam Therapeutics presented updated Phase 1/2 data for BEAM-302 at ATS 2026, reinforcing the company’s in vivo base-editing platform and supporting plans for an accelerated approval strategy in Alpha-1 Antitrypsin Deficiency (AATD).
Beam Therapeutics announced updated biomarker data from the Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel), reinforcing its position as the leading base-edited cell therapy program in sickle cell disease ahead of a planned…
Agios Pharmaceuticals submitted a supplemental NDA to the FDA seeking accelerated approval of mitapivat for sickle cell disease, positioning the oral PKR activator in a highly competitive emerging therapeutic class.
Incyte announced more than 20 hematology and oncology presentations for EHA 2026, highlighted by plenary Phase 3 frontMIND data in frontline diffuse large B-cell lymphoma (DLBCL) and new clinical data for INCA033989, a mutation-specific…
